You are here

Herbert Smith Freehills advises joint sponsors on 3D Medicines' Hong Kong IPO 史密夫斐尔律师事务所作为联席保荐人律师为思路迪香港上市提供法律服务

15 December 2022 | China
News

Share

Leading international law firm Herbert Smith Freehills has advised CICC and CSCI as joint sponsors of 3D Medicines Inc. (01244.HK)’s mainboard listing on the Stock Exchange of Hong Kong.

3D Medicines specialises in the research and development of oncology therapies for cancer patients, especially those who require long-term care. As of the latest practicable date, the company has built a pipeline of one core product and 11 drug candidates, of which the core product envafolimab was approved in November 2021 and commercialised in December 2021, and another seven drug candidates are in clinical stage. 3D Medicines listed on 15 December 2022.

"We are delighted to have worked with 3D Medicines, a leading bio-pharmaceutical company, on its successful listing on the Hong Kong Stock Exchange,” said Beijing partner Isaac Chen. "We congratulate 3D Medicines and the joint sponsors on this successful IPO and wish them continued success."

Herbert Smith Freehills leads the legal market on Hong Kong IPOs. The firm has advised on eleven successful listings in Hong Kong for the year to date. Notably, Herbert Smith Freehills has advised Onewo Inc. (02602.HK), Lygend Resources & Technology Co., Ltd. (02245.HK), and JL MAG Rare-Earth Co., Ltd. (06680.HK), respectively the 4th, 6th and 7th largest IPO.

"Capital markets demonstrate resilience to meet fundraising needs even in volatile conditions," said Beijing partner Zhong Wang. "We look forward to continuing to support Chinese companies to access international investors through Hong Kong."

Isaac and Zhong jointly led the team advising joint sponsors, assisted by senior associate Chanan Ng, associates Sannie Xue, Yuda Chen and Ken Li, and legal assistants Emma Chen and Aiye Jia on the Hong Kong law aspects of the IPO, and associates Brian Ge, Kathy Zhang and Yuanyuan Yin on the US law aspects of the IPO. Partners Jason Sung and Jin Kong (senior registered foreign lawyer - New York, USA) also provided support.

Legal manager Marine Jin led Herbert Smith Freehills Kewei Joint Operation’s Alternative Legal Services business to provide high-efficiency solutions for verification and other document-intensive processes during the offering, assisted by legal specialists Ling Jiang and Rainie Mao, senior legal analyst Shawna Peng, and legal analysts Ling Sun and Huaqian Zhang.

国际领先的律师事务所史密夫斐尔于思路迪(01244.HK)在香港联交所主板上市的项目中担任联席保荐人中金公司和中信建投国际的律师并提供法律服务。

思路迪致力于为癌症患者,尤其是那些需要长期治疗的患者研发肿瘤药物。截至最后实际可行日期,公司已建立一条包含一款核心产品及11款候选药物的管线,其中核心产品恩沃利单抗已于2021年11月获批并于2021年12月商业化,另有七款其他候选药物处于临床阶段。思路迪于2022年12月15日上市。

史密夫斐尔北京办公室合伙人陈敏(Isaac Chen)表示:“思路迪是一家领先的生物医药公司,我们很高兴助力其成功在联交所上市。衷心向思路迪和联席保荐人表示祝贺,并祝愿他们不断取得成功。”

史密夫斐尔在就香港IPO上市提供法律服务方面处于市场领先地位。截至目前,本所在2022年已为11家公司在香港上市提供法律服务。值得一提的是,史密夫斐尔参与的万物云(02602.HK)、力勤资源(02245.HK)和金力永磁(06680.HK) IPO,分别创下了2022年至今香港第四、第六和第七大IPO。

史密夫斐尔北京办公室合伙人王重(Zhong Wang)表示:“资本市场表现出了韧性,即使在动荡的市场环境下也能满足融资需求。我们期望继续支持中国企业通过香港资本市场接触国际投资者。”

合伙人陈敏和王重联合率领律师团队为此次上市的联席保荐人提供法律服务。香港法方面主要团队成员包括伍庆哲(Senior Associate)、薛姗姗(Associate)、陈昱达(Associate)、李德明(Associate)、陈阿婷(Legal Assistant)和贾瑷烨(Legal Assistant)。葛轶(Associate)、张凯西(Associate)和尹圆圆(Associate)就美国法方面提供法律服务。合伙人宋子淳和孔瑾(Senior Registered Foreign Lawyer)也为此次上市提供了支持。

金燊(Legal Manager)率领的科伟史密夫斐尔联营办公室替代性法律服务(ALT)联合团队在上市项目期间为招股书验证及其他文件密集型工作提供高效率的解决方案。江凌(Legal Specialist)、茅睿恬(Legal Specialist)、彭祺程(Senior Legal Analyst)、孙泠(Legal Analyst) 和张华倩(Legal Analyst)提供支持。

See how we help our clients in

Equity Capital Markets

Learn More

Key Contacts

Media Contact

For further information on this news article, please contact:

Sally Greig, Head of Communications, Asia

Hong Kong
Tel: 
+852 21014624

VIVIAN HUANG, COMMUNICATIONS MANAGER, CHINA

Beijing
Tel: 
+86 10 65355025